Patents by Inventor Serdar DURDAGI

Serdar DURDAGI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DRG-MDM2-4 for use as a novel mouse double minute 2 (MDM2) inhibitor
    Patent number: 12661354
    Abstract: The invention relates to compounds according to formula (I) and pharmaceutically acceptable derivatives thereof for use as novel inhibitors of Mouse Double Minute 2 (MDM2) activity by inhibiting interactions between MDM2 and its natural negative regulator, p53. Pharmaceutical compositions containing a compound of Formula (I), or a derivative thereof, including compositions that also contain one or more additional antiproliferative agents, can be used in methods of treating proliferative diseases, including various cancers.
    Type: Grant
    Filed: February 17, 2021
    Date of Patent: June 23, 2026
    Assignees: BAHCESEHIR UNIVERSITESI, ISTANBUL TEKNIK UNIVERSITESI
    Inventors: Serdar Durdagi, Timucin Avsar, Muge Didem Orhan, Maide Nur Paksoy, Gulsah Aydin, Mine Yurtsever
  • DRG-MDM2-1 for use as a novel Mouse Double Minute 2 (MDM2) inhibitor
    Patent number: 12595232
    Abstract: The invention relates to compound shown with formula (I) or a pharmaceutically acceptable derivative thereof for use as a novel inhibitor of MDM2 activity.
    Type: Grant
    Filed: February 16, 2021
    Date of Patent: April 7, 2026
    Assignees: BAHCESEHIR UNIVERSITESI, ISTANBUL TEKNIK UNIVERSITESI
    Inventors: Timucin Avsar, Serdar Durdagi, Muge Didem Orhan, Maide Nur Paksoy, Gulsah Aydin, Mine Yurtsever
  • 2-(1,8-DIETHYL-1,3,4,9-TETRAHYDROPYRANO[3,4-B]INDOL-1-YL)-1-(4-METHYLPIPERAZIN-1-YL)ETHAN-1-ONE ETODOLAC DERIVATIVE AS EUKARYOTIC ELONGATION FACTOR 2 KINASE (EEF2K) INHIBITOR FOR TARGETED CANCER THERAPY
    Publication number: 20260049091
    Abstract: A compound derivative is provided, where R in the compound of formula A is 4-methylpiperazine, and the compound derivative can be used in the treatment of cancer and other diseases through the development of small molecules as eukaryotic elongation factor 2 kinase (eEF2K) enzyme inhibitors that are active in breast, pancreatic, brain, ovarian, lung, skin and blood cancers.
    Type: Application
    Filed: March 29, 2024
    Publication date: February 19, 2026
    Applicant: BAHCESEHIR UNIVERSITESI
    Inventors: Ferah COMERT ONDER, Bulent OZPOLAT, Serdar DURDAGI, Mehmet AY, Pinar SIYAH
  • 2-(L,8-DIETHYL-1,3,4,9-TETRAHYDROPYRANO[3,4-B]INDOL-1-YL)-N-(2-(PIPERIDIN-1 YL)ETHYL)ACETAMIDE ETODOLAC DERIVATIVE AS A EUKARYOTIC ELONGATION FACTOR 2 KINASE (EEF2K) INHIBITOR FOR TARGETED CANCER THERAPY
    Publication number: 20260022126
    Abstract: A compound derivative is provided, where R in the compound of formula A is (2-(2-(piperidin-1-yl)ethane-1-amine), and the compound derivative can be used in the treatment of cancer and other diseases through the development of small molecules as eukaryotic elongation factor 2 kinase (eEF2K) enzyme inhibitors that are active in breast, pancreatic, brain, ovarian, lung, skin and blood cancers.
    Type: Application
    Filed: March 29, 2024
    Publication date: January 22, 2026
    Applicant: BAHCESEHIR UNIVERSITESI
    Inventors: Ferah COMERT ONDER, Bulent OZPOLAT, Serdar DURDAGI, Mehmet AY, Pinar SIYAH
  • MAO-B inhibitor DRG-MAOB-1 for use in treatment of neurodegenerative diseases
    Patent number: 12528794
    Abstract: The invention relates to compound shown with formula (I) or a pharmaceutically acceptable derivative thereof for use as a novel inhibitor of MAO-B.
    Type: Grant
    Filed: February 25, 2021
    Date of Patent: January 20, 2026
    Assignees: BAHCESEHIR UNIVERSITESI, ISTANBUL TEKNIK UNIVERSITESI, AGRI IBRAHIM CECEN UNIVERSITESI STRATEJI DAIRE BASK., ISTANBUL GEDIK UNIVERSITESI
    Inventors: Serdar Durdagi, Mine Yurtsever, Busecan Aksoydan, Yusuf Serhat Is, Murat Senturk
  • 2-(1,8-DIETHYL-1,3,4,9-TETRAHYDROPYRANO[3,4-B]INDOL-1-YL)-1-(PIPERIDIN-1-YL)ETHAN-1-ONE ETODOLAC DERIVATIVE AS EUKARYOTIC ELONGATION FACTOR 2 KINASE (EEF2K) INHIBITOR FOR TARGETED CANCER THERAPY
    Publication number: 20260015359
    Abstract: A compound derivative is provided, where R in the compound of formula A is piperidine, and the compound derivative can be used in the treatment of cancer and other diseases through the development of small molecules as eukaryotic elongation factor 2 kinase (eEF2K) enzyme inhibitors that are active in breast, pancreatic, brain, ovarian, lung, skin and blood cancers.
    Type: Application
    Filed: March 29, 2024
    Publication date: January 15, 2026
    Applicant: BAHCESEHIR UNIVERSITESI
    Inventors: Ferah COMERT ONDER, Bulent OZPOLAT, Serdar DURDAGI, Mehmet AY, Pinar SIYAH
  • DRG-MDM2-6 for use as a novel mouse double minute 2 (MDM2) inhibitor
    Patent number: 12502392
    Abstract: The invention relates to compound shown with formula (I) or a pharmaceutically acceptable derivative thereof for use as a novel inhibitor of MDM2 activity.
    Type: Grant
    Filed: February 17, 2021
    Date of Patent: December 23, 2025
    Assignees: BAHCESEHIR UNIVERSITESI, ISTANBUL TEKNIK UNIVERSITESI
    Inventors: Mine Yurtsever, Muge Didem Orhan, Maide Nur Paksoy, Gulsah Aydin, Timucin Avsar, Serdar Durdagi
  • Selective MAO-B inhibitor DRG-MAOB-2 for use in treatment of neurodegenerative diseases
    Patent number: 12478613
    Abstract: The invention relates to compound shown with formula (I) or a pharmaceutically acceptable derivative thereof for use as a novel inhibitor of MAO-B.
    Type: Grant
    Filed: February 25, 2021
    Date of Patent: November 25, 2025
    Assignees: BAHCESEHIR UNIVERSITESI, AGRI IBRAHIM CECEN UNIVERSITESI STRATEJI DAIRE BASK., ISTANBUL GEDIK UNIVERSITESI, ISTANBUL TEKNIK UNIVERSITESI REKTORLUGU
    Inventors: Serdar Durdagi, Mine Yurtsever, Yusuf Serhat Is, Busecan Aksoydan, Murat Senturk
  • Physics-driven discovery of novel small therapeutic compounds for use as a BCL-2 inhibitor
    Patent number: 12435074
    Abstract: The invention relates to compound shown with formula (I) or a pharmaceutically acceptable derivative thereof for use as a novel inhibitor of BCL-2.
    Type: Grant
    Filed: February 10, 2021
    Date of Patent: October 7, 2025
    Assignee: BAHCESEHIR UNIVERSITESI
    Inventors: Muge Didem Orhan, Serdar Durdagi, Berna Dogan, Seyma Calis, Gurbet Cacan, Timucin Avsar
  • Physics-driven discovery of novel small therapeutic compounds for use as a BCL-2 inhibitor
    Patent number: 12398128
    Abstract: The invention relates to compound shown with formula (I) or a pharmaceutically acceptable derivative thereof for use as a novel inhibitor of BCL-2.
    Type: Grant
    Filed: February 10, 2021
    Date of Patent: August 26, 2025
    Assignee: BAHCESEHIR UNIVERSITESI
    Inventors: Serdar Durdagi, Timucin Avsar, Muge Didem Orhan, Gurbet Cacan, Berna Dogan, Seyma Calis
  • Physics-driven discovery of novel small therapeutic compounds for use as a BCL-2 inhibitor
    Patent number: 12384746
    Abstract: The invention relates to compound shown with formula (I) or a pharmaceutically acceptable derivative thereof for use as a novel inhibitor of BCL-2.
    Type: Grant
    Filed: February 10, 2021
    Date of Patent: August 12, 2025
    Assignee: BAHCESEHIR UNIVERSITESI
    Inventors: Muge Didem Orhan, Timucin Avsar, Berna Dogan, Gurbet Cacan, Seyma Calis, Serdar Durdagi
  • Physics-driven discovery of novel small therapeutic compounds for use as a BCL-2 inhibitor
    Patent number: 12318368
    Abstract: The invention relates to compound shown with formula (I) or a pharmaceutically acceptable derivative thereof for use as a novel inhibitor of BCL-2.
    Type: Grant
    Filed: February 10, 2021
    Date of Patent: June 3, 2025
    Assignee: BAHCESEHIR UNIVERSITESI
    Inventors: Berna Dogan, Serdar Durdagi, Gurbet Cacan, Seyma Calis, Timucin Avsar, Muge Didem Orhan
  • Physics-driven discovery of novel small therapeutic compounds for use as a BCL-2 inhibitor
    Patent number: 12297175
    Abstract: The invention relates to compound shown with formula (I) for a pharmaceutically acceptable derivative thereof for use as a novel inhibitor of BCL-2.
    Type: Grant
    Filed: February 10, 2021
    Date of Patent: May 13, 2025
    Assignee: BAHCESEHIR UNIVERSITESI
    Inventors: Muge Didem Orhan, Berna Dogan, Seyma Calis, Gurbet Cacan, Timucin Avsar, Serdar Durdagi
  • DRG-MDM2-2 FOR USE AS A NOVEL MOUSE DOUBLE MINUTE 2 (MDM2) INHIBITOR
    Publication number: 20240270730
    Abstract: The invention relates to compound shown with formula I or a pharmaceutically acceptable derivative thereof for use as a novel inhibitor of MDM2 activity.
    Type: Application
    Filed: February 17, 2021
    Publication date: August 15, 2024
    Inventors: Serdar DURDAGI, Muge Didem ORHAN, Timucin AVSAR, Mine YURTSEVER, Maide Nur PAKSOY, Gulsah AYDIN
  • PHYSICS-DRIVEN DISCOVERY OF NOVEL SMALL THERAPEUTIC COMPOUNDS FOR USE AS A BCL-2 INHIBITOR
    Publication number: 20230109522
    Abstract: The invention relates to compound shown with formula (I) or a pharmaceutically acceptable derivative thereof for use as a novel inhibitor of BCL-2.
    Type: Application
    Filed: February 10, 2021
    Publication date: April 6, 2023
    Inventors: Serdar DURDAGI, Timucin AVSAR, Muge Didem ORHAN, Gurbet CACAN, Berna DOGAN, Seyma CALIS
  • PHYSICS-DRIVEN DISCOVERY OF NOVEL SMALL THERAPEUTIC COMPOUNDS FOR USE AS A BCL-2 INHIBITOR
    Publication number: 20230099876
    Abstract: The invention relates to compound shown with formula (I) or a pharmaceutically acceptable derivative thereof for use as a novel inhibitor of BCL-2.
    Type: Application
    Filed: February 10, 2021
    Publication date: March 30, 2023
    Inventors: Muge Didem ORHAN, Serdar DURDAGI, Berna DOGAN, Seyma CALIS, Gurbet CACAN, Timucin AVSAR
  • DRG-MDM2-6 FOR USE AS A NOVEL MOUSE DOUBLE MINUTE 2 (MDM2) INHIBITOR
    Publication number: 20230098888
    Abstract: The invention relates to compound shown with formula (I) or a pharmaceutically acceptable derivative thereof for use as a novel inhibitor of MDM2 activity.
    Type: Application
    Filed: February 17, 2021
    Publication date: March 30, 2023
    Inventors: Mine YURTSEVER, Muge Didem ORHAN, Maide Nur PAKSOY, Gulsah AYDIN, Timucin AVSAR, Serdar DURDAGI
  • A NOVEL SELECTIVE MAO-B INHIBITOR DRG-MAOB-2 FOR USE IN TREATMENT OF NEURODEGENERATIVE DISEASES
    Publication number: 20230088611
    Abstract: The invention relates to compound shown with formula (I) or a pharmaceutically acceptable derivative thereof for use as a novel inhibitor of MAO-B.
    Type: Application
    Filed: February 25, 2021
    Publication date: March 23, 2023
    Inventors: Serdar DURDAGI, Mine Didem YURTSEVER, Yusuf Serhat IS, Busecan Serhat AKSOYDAN, Murat SENTURK
  • A NOVEL MAO-B INHIBITOR DRG-MAOB-1 FOR USE IN TREATMENT OF NEURODEGENERATIVE DISEASES
    Publication number: 20230093302
    Abstract: The invention relates to compound shown with formula (I) or a pharmaceutically acceptable derivative thereof for use as a novel inhibitor of MAO-B.
    Type: Application
    Filed: February 25, 2021
    Publication date: March 23, 2023
    Inventors: Serdar DURDAGI, Mine Didem YURTSEVER, Busecan AKSOYDAN, Yusuf Serhat IS, Murat SENTURK
  • PHYSICS-DRIVEN DISCOVERY OF NOVEL SMALL THERAPEUTIC COMPOUNDS FOR USE AS A BCL-2 INHIBITOR
    Publication number: 20230088086
    Abstract: The invention relates to compound shown with formula (I) for a pharmaceutically acceptable derivative thereof for use as a novel inhibitor of BCL-2.
    Type: Application
    Filed: February 10, 2021
    Publication date: March 23, 2023
    Inventors: Muge Didem ORHAN, Berna DOGAN, Seyma CALIS, Gurbet CACAN, Timucin AVSAR, Serdar DURDAGI